Abstract
BackgroundClinical trials for ovarian cancer using immune checkpoint inhibitors (ICI) as monotherapy have failed to show an improvement in survival, however, improved response rates and survival have been achieved with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
